Worth reading
95Important
Scored from 1 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
270
USD millionWording
Conditional
How definitive the wording is.This transaction
The acquisitionDisclosing companyOLYMPUS CORPORATION
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
Execution Date / Effective Date1 June 2026 (completed)
Target company
Research and development and manufacture of biodegradable balloon rectal spacers for prostate cancer
Location Netanya, IsraelShare capital ¥11,451 million (as of 31 December 2025)Date of incorporation 22 September 2004
Consideration and expenses
Acquisition price$270 million (approximately ¥43.3 billion)
Impact on Business Performance
Currently under review
Procedures and assumptions
Management structure after acquisitionChairman and CEO Itay Barnea is listed as the representative, but the post-acquisition management structure is not disclosed
| Item | Details |
|---|---|
| Transaction name | The acquisition |
| Name of the Subject Company | BioProtect Ltd. |
| Business Description of the Subject Company | Research and development and manufacture of biodegradable balloon rectal spacers for prostate cancer |
| Location of the Subject Company | Netanya, Israel |
| Capital Stock of the Subject Company | ¥11,451 million (as of 31 December 2025) |
| Date of Establishment of the Subject Company | 22 September 2004 |
| Acquisition price | $270 million (approximately ¥43.3 billion) |
| Number of shares acquired | 16,925,621 shares |
| Voting rights ownership percentage | Before 0% → after 100% |
| Impact on Business Performance | Currently under review |
| Execution Date / Effective Date | 1 June 2026 (completed) |
| Management structure after acquisition | Chairman and CEO Itay Barnea is listed as the representative, but the post-acquisition management structure is not disclosed |
Items this document does not state (20)
Counterparty nameNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Date of board resolutionContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to Execution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The acquisition of shares announced on 26 May 2026 was completed on 1 June 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.